Tyrosine Kinase
- IGFBR(1)
- Bcr-Abl(67)
- Ack1(2)
- Axl(6)
- ALK(56)
- BMX Kinase(3)
- Broad Spectrum Protein Kinase Inhibitor(10)
- c-FMS(35)
- c-Kit(56)
- c-MET(84)
- c-RET(0)
- CSF-1R(3)
- DDR1/DDR2 Receptor(1)
- EGFR(235)
- EphB4(1)
- FAK(33)
- FGFR(95)
- FLT3(85)
- HER2(12)
- IGF1R(33)
- Insulin Receptor(44)
- IRAK(28)
- ITK(10)
- Lck(1)
- LRRK2(22)
- PDGFR(104)
- PTKs/RTKs(3)
- Pyk2(6)
- ROR(38)
- Spleen Tyrosine Kinase (Syk)(32)
- Src(97)
- Tie-2 (4)
- Trk(39)
- VEGFR(181)
- Kinase(0)
- Discoidin Domain Receptor(15)
- DYRK(29)
- Ephrin Receptor(12)
- ROS(14)
- RET(29)
- TAM Receptor(29)
Products for Tyrosine Kinase
- Cat.No. Product Name Information
- GC31526 Insulin levels modulator Insulin levels modulator could be used to treat diabetes.
- GC31303 Insulin(cattle) (Insulin from bovine pancreas) Insulin cattle (Insulin from bovine pancreas) is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells.
-
GC17158
IRAK inhibitor 1
IRAK4-IN-1
An IRAK4 inhibitor - GC12651 IRAK inhibitor 2
- GC11103 IRAK inhibitor 3
- GC16264 IRAK inhibitor 4
- GC36328 IRAK inhibitor 4 trans IRAK inhibitor 4 (trans) is the trans form of IRAK inhibitor 4.
- GC17371 IRAK inhibitor 6 An IRAK4 inhibitor
- GC15999 IRAK-1-4 Inhibitor I A benzimidazole
- GC62583 IRAK-4 protein kinase inhibitor 2 IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC50 of 4 μM.
- GC31688 IRAK4-IN-1 IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.
- GC71135 IRAK4-IN-20 IRAK4-IN-20 (Compound BAY-1834845) is an orally active IRAK4 inhibitor with an IC50 of 3.55 nM.
-
GC69288
IRAK4-IN-21
IRAK4-IN-21 (Compound 17) is an orally effective and selective potent IRAK4 inhibitor with IC50 values of 5 and 56 nM for IRAK4 and TAK1, respectively. It can effectively inhibit the production of IL-23 (IC50=0.17 μM) and may be used in research on autoimmune diseases such as psoriasis vulgaris and psoriatic arthritis.
-
GC69289
IRAK4-IN-22
IRAK4-IN-22 (compound 18) is an orally effective and selective potent IRAK4 inhibitor with IC50 values of 3 and 17 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 can effectively inhibit the production of IL-23 (IC50=0.10 μM), which can be used in research on autoimmune diseases such as psoriasis vulgaris and psoriatic arthritis.
- GC38799 IRAK4-IN-4 IRAK4-IN-4 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor extracted from patent CN107163044A, Compound15, has an IC50 of 2.8 nM.
- GC61944 IRAK4-IN-6 IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma.
-
GC13961
ISCK03
c-Kit Inhibitor II,Stem-Cell Factor/c-Kit Inhibitor
inhibitor of SCF-mediated c-kit activation -
GC12167
ITK inhibitor
Potent ITK inhibitor
- GC36354 ITK inhibitor 2 ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor extracted from patent WO2011065402A1, compound 4, with an IC50 of 2 nM.
-
GC16869
Ixabepilone
Azaepothilone B, BMS-247550
A broad-spectrum anticancer agent - GC62500 JAK2-IN-7 JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities.
- GC62665 JAK2/FLT3-IN-1 TFA JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity.
- GC50706 JBJ-03-142-02
-
GC62632
JBJ-04-125-02
JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active EGFR inhibitor with an IC50 of 0.26 nM for EGFRL858R/T790M. JBJ-04-125-02 can inhibit cancer cell proliferation and EGFRL858R/T790M/C797S signaling. JBJ-04-125-02 has anti-tumor activities.
-
GC67690
JBJ-09-063 hydrochloride
JBJ-09-063 hydrochloride is a mutation selective allosteric EGFR inhibitor
- GC67860 JBJ-09-063 TFA
- GC19205 JH-II-127 JH-II-127 is a highly potent, selective, and brain penetrant LRRK2 inhibitor, with IC50 of 6.6 nM, 2.2 nM ,47.7 nM for LRRK2-wild-type, LRRK2-G2019S, LRRK2-A2016T.
- GC33062 JH-VIII-157-02 JH-VIII-157-02 is a structural analogue of alectinib, acts as an ALK inhibitor, and shows an IC50 of 2 nM for echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) G1202R in cells.
- GC63925 JH-X-119-01 JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor.
-
GC18168
JI-101
CGI1842
An orally active inhibitor
- GC65436 JND3229 JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma.
- GC18030 JNJ 28871063 hydrochloride ErbB receptor family inhibitor
- GC38502 JNJ-10198409 A potent PDGF tyrosine kinase inhibitor
- GC14544 JNJ-10198409 inhibitor of platelet-derived growth factor (PDGF-BB) tyrosine kinase
- GC12585 JNJ-38877605 C-Met inhibitor,ATP-competitive
- GC33266 JNJ-38877618 JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively.
-
GC32995
JNJ-47117096 hydrochloride (MELK-T1 hydrochloride)
MELK-T1 hydrochloride
JNJ-47117096 hydrochloride (MELK-T1 hydrochloride) is potent and selective MELK inhibitor, with an IC50 of 23 nM, also effectively inhibits Flt3, with an IC50 of 18 nM. - GC70499 JNJ-49095397 JNJ-49095397 (RV568) is an inhaled narrow-spectrum kinase inhibitor (NSKI) against both the α and γ isoforms of p38 MAPK.
-
GC69318
JNJ-61803534
JNJ-61803534 is an effective and orally active RORγt inverse agonist with an IC50 of 9.6 nM. It has anti-inflammatory activity and inhibits the production of IL-17A in human CD4+ T cells under Th17 differentiation conditions.
-
GC69321
JTE-952
JTE-952 is an orally active, type II selective inhibitor of colony-stimulating factor-1 receptor (CSF-1R/cFMS) that effectively inhibits CSF1R and TrkA with IC50 values of 13 nM and 261 nM, respectively. It can be used for research related to arthritis.
-
GC11362
K 252a
SF 2370
A protein kinase inhibitor -
GN10497
Kaempferitrin
BRN 0073958, Grosvenorine II, Kaempferol 3,7-O-α-Dirhamnoside, Lespedin
- GC17638 KB SRC 4 KB SRC 4 is a potent, and highly selective c-Src inhibitor, with a Ki of 44 nM and a Kd of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity.
-
GC32625
KDR-in-4
KDR-in-4
KDR-in-4 (KDR-in-4) is a potent kinase insert domain-containing receptor (KDR/VEGFR2) inhibitor with an IC50 of 7 nM. - GC63943 KH-CB20 KH-CB20, an E/Z mixture, is a potent and selective inhibitor of CLK1 and the closely related isoform CLK4, with an IC50 of 16.5 nM for CLK1.
-
GC13264
Ki20227
Ki 20227;Ki-20227
A c-Fms kinase inhibitor - GC11666 Ki8751 VEGFR-2 inhibitor,potent and selective
- GC72285 KLTWQELYQLKYKGI KLTWQELYQLKYKGI (QK) is a VEGF mimicking peptide, binds to the VEGF receptors and competes with VEGF.
- GC13902 KRCA 0008 Ack1 and anaplastic lymphoma kinase (ALK) dual inhibitor
- GC12590 KRN 633 VEGFR inhibitor,ATP-competitive
- GC10626 KU14R
- GC14592 KW 2449 A multi-kinase inhibitor
- GC10523 KX1-004 Pp60c-src inhibitor
-
GC14288
KX2-391
KX 01, Tirbanibulin
KX2-391 (KX2-391) is an inhibitor of Src that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. - GC10222 KX2-391 dihydrochloride A Src kinase inhibitor
- GC50137 KYL KYL, an antagonistic peptide, selectively targets EphA4 receptor.
- GC32044 L 601920-0 (Methyl-3β-hydroxycholenate) L 601920-0 (Methyl-3β-hydroxycholenate) is a ROR gamma modulator extracted from patent US20110263046 A1, in figure 2.
-
GC44085
L-Sulforaphene
Raphanin, (S)-Sulforaphene
L-Sulforaphene, isolated from radish seeds, exhibits an ED50 against velvetleaf seedlings approximately 2 x 10-4 M. L-Sulforaphene promotes cancer cells apoptosis and inhibits migration via inhibiting EGFR, p-ERK1/2, NF‐κB and other signals. -
GC36423
Lanraplenib
GS-9876, GS-SYK
A Syk inhibitor -
GC38630
Lanraplenib succinate
GS-9876 succinate
Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. -
GC13608
Lapatinib
GW572016; GW2016
A dual inhibitor of EGFR and ErbB2 -
GC25559
Lapatinib (GW-572016) Ditosylate
GW-572016
Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. -
GC16593
Lapatinib Ditosylate
GW572016 ditosylate monohydrate; GW2016 ditosylate monohydrate
Lapatinib Ditosylate is a selective dual inhibitor of ErbB-2 and EGFR with IC50 value against ErbB-2 and EGFR of 9.2 and 10.8 nM in vitro, respectively. -
GC67759
Lapatinib-d4
GW572016-d4; GW2016-d4
-
GC69356
Laprituximab
J2898A
Laprituximab (J2898A) is a humanized IgG1 antibody against EGFR that can be used to synthesize ADC IMGN289.
-
GC69358
Larotinib mesylate hydrate
Larotinib mesylate hydrate is an effective, broad-spectrum, orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target, with an IC50 of 0.6 nM.
-
GC16021
Lavendustin A
NSC 678027, RG-14355
EGFR tyrosine kinase inhibitor -
GC19218
Lazertinib
YH25448
Lazertinib is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer. - GC70315 LCB 03-0110 LCB 03-0110, a thienopyridine derivative, is a potent pan-discoidin domain receptor/c-Src family tyrosine kinase inhibitor.
-
GC13117
Lck Inhibitor
Lymphocyte-specific Protein Tyrosine Kinase, RK-24466
A selective inhibitor of lymphocyte-specific protein tyrosine kinase - GC36430 Lck inhibitor 2 Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively
- GC14241 LDC1267 TAM kinase inhibitor,highly selective
-
GC14552
LDK378
LDK 378;LDK-378;Ceritinib
LDK378 (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. - GC17452 LDK378 dihydrochloride
-
GC50327
LDN 193189 dihydrochloride
DM-3189
Potent and selective ALK2 and ALK3 inhibitor; promotes neural induction of hPSCs - GC33086 LDN-192960 LDN-192960 is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively.
- GC44047 LDN-192960 (hydrochloride) LDN-192960 is an inhibitor of haspin protein kinase and dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) with IC50 values of 10 and 48 nM, respectively.
- GC38403 LDN-192960 hydrochloride LDN-192960 hydrochloride is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively.
-
GC16580
LDN-193189
LDN 193189;LDN193189
ALK inhibitor,potent and selective - GC16798 LDN-211904 LDN-211904 (compound 32) is a potent and selective EphB3 inhibitor with an IC50 of 0.079 μM. LDN-211904 shows good metabolic stability in mouse liver microsomes. LDN-211904 with cetuximab could be effective in inhibiting STAT3-activated CSC stemness and cetuximab resistance in CRC.
- GC17035 LDN-212854 BMP receptor inhibitor,potent and selective
- GC13225 LDN-214117 potent and selective ALK2 inhibitor
-
GC14931
LDN193189 Hydrochloride
LDN 193189 hydrochloride; LDN-193189 hydrochloride
LDN193189 Hydrochloride is a selective inhibitor of the transcriptionally active morphogenetic protein (BMP) type I receptor, a family of BMP receptors that includes activin receptor-like kinases (ALK1, ALK2, ALK3, and ALK6). LDN193189 Hydrochloride inhibits ALK2 and ALK3 with IC50 values of 5nM and 30nM, respectively. -
GC15454
Lenvatinib (E7080)
E-7080, ER-203492-00
Lenvatinib (E7080) (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities. -
GC36438
Lenvatinib mesylate
E-7080
An inhibitor of VEGFR2 and VEGFR3 -
GC17033
Lestaurtinib
CEP-701; KT-5555
A potent JAK2 and PRK1 kinase inhibitor -
GC17958
Linifanib (ABT-869)
Linifanib
Linifanib (ABT-869) (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (ABT-869) shows prominent antitumor activity. Linifanib (ABT-869) has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib (ABT-869) is a specific miR-10b inhibitor that blocks miR-10b biogenesis. -
GC15749
Linsitinib
OSI 906; OSI-906; OSI906
IGF1R/IR inhibitor,potent and novel - GC47570 Lipoxygenin An inhibitor of 5-LO
- GC17835 LM 22A4 tropomyosin-related kinase B (TrkB) agonist
- GC30770 LM22B-10 An activator of TrkB and TrkC
-
GC36425
LOXO-101 (Larotrectinib)
ARRY-470, Larotrectinib
LOXO-101 (Larotrectinib) (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C). - GC15282 LOXO-101 (Larotrectinib) sulfate LOXO-101 (Larotrectinib) sulfate (LOXO-101 sulfate; ARRY-470 sulfate) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).
-
GC19547
LOXO-292
selpercatinib
LOXO-292 (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. LOXO-292 has anticancer activity. - GC65390 LRRK2 inhibitor 1 LRRK2 inhibitor 1 is a potent, selective and oral LRRK2 inhibitor with an pIC50 of 6.8.
-
GC10809
LRRK2-IN-1
Leucine-rich repeat kinase 2 IN-1
A selective LRRK2 inhibitor -
GC69402
LRRK2-IN-7
LRRK2-IN-7 is an effective, selective, CNS-penetrant LRRK2 kinase inhibitor with an IC50 of 0.9 nM. The selectivity of LRRK2-IN-7 is over 1000-fold for other kinases, ion channels and CYP enzymes.
-
GC69410
Lumretuzumab
Anti-Human ERBB3 Recombinant Antibody
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized monoclonal antibody that targets HER3 (ERBB3) and can be used for cancer research.
-
GC13848
LY2784544
Gandotinib
Potent inhibitor of JAK2 -
GC11057
LY2801653
Merestinib
A MET kinase inhibitor